OncoMatch/Clinical Trials/NCT06667908
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Is NCT06667908 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Durvalumab and JNJ-90301900 for carcinoma, non-small-cell lung.
Treatment: JNJ-90301900 · Durvalumab · Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin · Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel — The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Connecticut Health Center · Farmington, Connecticut
- Yale University · New Haven, Connecticut
- University of Miami · Miami, Florida
- Orlando Health Cancer Institute · Orlando, Florida
- Emory University Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06667908 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages